Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

How the TB Bacterium Tricks the Immune System

By Drug Discovery Trends Editor | June 3, 2015

Source: ShutterstockScientists at EPFL have discovered how the tuberculosis bacterium can trick the patient’s immune cells to lower their defenses.

Tuberculosis is caused by the bacterium Mycobacterium tuberculosis and it affects over 12 million people globally. When the bacterium infects a person, the body’s immune response is critical to how the disease will progress; either helping the body fight the bacterium or, if certain key molecules become involved, actually exacerbating the infection. EPFL scientists now show how the tuberculosis bacterium co-opts mechanisms of the immune system to its own advantage. The study is published in Cell Host & Microbe.

The body fights tuberculosis: Inflammasome, interleukins, interferons

When M. tuberculosis infects a person, it attacks the lungs’ first-response immune cells, the macrophages. The immune response by the macrophages involves a complex of four different proteins called the “inflammasome”. The main role of the inflammasome is to prepare certain immunity proteins in the macrophages, which are called “interleukins”. When M. tuberculosis infects the lungs, interleukins from the macrophages are in the first line of defense.

But if it is left uncontrolled, this defense can also cause serious damage to the patient. To prevent this, macrophages also release another group of proteins called “type I interferons”. While interferons are important for defending the body against viruses, when it comes to tuberculosis they actually help the bacterium, thereby exacerbating the disease. And although the interleukin-inflammation part of the immune response is rather well understood, the part involving interferons has been elusive.

DNA trickery

The lab of Andrea Ablasser at EPFL, in collaboration with the lab of Stewart Cole, has now discovered how M. tuberculosis carries out a subtle assault on our immune defenses. The key is a molecule called cGAS, which is found in the lung’s macrophages, and is part of a group of DNA-sensor molecules; in short, cGAS patrols the inside of macrophages, and when it detects unidentified pieces of DNA, such as those released by M. tuberculosis, it triggers an immune response from the macrophages.

The tuberculosis bacterium uses a specialized secretion system to release its array of toxic proteins into macrophages. But, strangely, it also releases small bits of DNA, which are detected by sensing systems inside the macrophages, namely the inflammasome and cGAS. This causes macrophages to release two types of proteins: interleukin-1, which fights the bacterium, and type I interferons, which end up helping it.

Ablasser’s group used human and animal macrophages to study what happens when they are infected by M. tuberculosis. What they found was that the bacterium passes DNA bits into the macrophages, thereby tricking cGAS to signal the production of interferons, which reduce the immune response. In other words, the bacterium tricks the macrophages to cut back on their defense against it.

But the researchers did not stop there. They also showed that it is possible to manipulate M. tuberculosis in such a way that it can no longer activate the production of interferons through cGAS, while still keeping the production of interleukin-1 – and thus the body’s immune response – intact.

The study is the first to identify cGAS as a sensor for M. tuberculosis DNA, and also suggests that this method of molecular manipulation applies to other bacteria that use specialized secretion systems to infect cells. “Our work shows that tuberculosis is a far more sophisticated disease than previously thought,” said Andrea Ablasser, who is now working, among other projects, to identify the DNA pieces that M. tuberculosis uses to trick macrophages.

Source: Ecole Polytechnique Federale de Lausanne


Filed Under: Genomics/Proteomics

 

Related Articles Read More >

Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification
Spatial biology: Transforming our understanding of cellular environments
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
DNA helix 3D illustration. Mutations under microscope. Decoding genome. Virtual modeling of chemical processes. Hi-tech in medicine
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE